Literature DB >> 6851357

Low iodine diet in I-131 ablation of thyroid remnants.

H R Maxon, S R Thomas, A Boehringer, J Drilling, M I Sperling, J C Sparks, I W Chen.   

Abstract

A low-iodine diet was developed for used in decreasing iodine intake and excretion in patients undergoing evaluation with radioactive I-131 for ablation of thyroid remnants as treatment for thyroid cancer. It has been demonstrated to effectively lower iodine excretion to less than 25% of basal values. Preliminary calculations suggest that such iodine depletion may be potentially useful in increasing the radiation dose per mCi of administered activity in I-131 ablative therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6851357     DOI: 10.1097/00003072-198303000-00006

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  19 in total

1.  Low-iodine diet in the treatment of differentiated thyroid cancer with radioactive iodine.

Authors:  Martin Sonenberg
Journal:  Endocrine       Date:  2002-03       Impact factor: 3.633

Review 2.  ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?

Authors:  Daniele Barbaro; Frederik A Verburg; Markus Luster; Christoph Reiners; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

Review 3.  Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review.

Authors:  Anna M Sawka; Irada Ibrahim-Zada; Philip Galacgac; Richard W Tsang; James D Brierley; Shereen Ezzat; David P Goldstein
Journal:  Thyroid       Date:  2010-10       Impact factor: 6.568

4.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

Authors:  A S Alzahrani; G Mohamed; A Al Shammary; S Aldasouqi; S Abdal Salam; M Shoukri
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

5.  The success rate of initial (131)i ablation in differentiated thyroid cancer: comparison between less strict and very strict low iodine diets.

Authors:  Ik Dong Yoo; Sung Hoon Kim; Ye Young Seo; Jin Kyoung Oh; Joo Hyun O; Soo Kyo Chung
Journal:  Nucl Med Mol Imaging       Date:  2011-10-08

Review 6.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

Review 7.  Adverse reactions and drug interactions with radiopharmaceuticals.

Authors:  C B Sampson
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606

8.  Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy.

Authors:  Robbert B T Verkooijen; Marcel P M Stokkel; Jan W A Smit; Ernest K J Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

9.  Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.

Authors:  Seo Young Sohn; Joon Young Choi; Hye Won Jang; Hye Jeong Kim; Sang Man Jin; Se Won Kim; Sunghwan Suh; Kyu Yeon Hur; Jae Hyeon Kim; Jae Hoon Chung; Sun Wook Kim
Journal:  Thyroid       Date:  2013-06       Impact factor: 6.568

Review 10.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.